🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

522 results for “therapy” Clear

  1. Study which tests 3 medicines (SB27, EU sourced Keytruda, and US sourced Keytruda) in early or locally advanced non-small cell lung cancer patients who underwent surgery and adjuvant chemotherapy

    Samsung Bioepis NL B.V.

    Non-small cell lung cancer

    phase 1 other active

    1 trial

  2. The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)

    Sinobioway Cell Therapy Co.,

    Lymphoma

    phase 1 mab active

    1 trial

  3. Treatment of cancer with Immune Checkpoint Inhibition therapy boosted by High Intensity Focused Ultrasound Histotripsy (the iFOCUS study)

    Disc Medicine

    Metastatic or unresectable solid malignancies. Standard of care treatment options must not be available or not be considered feasible. Patients must have a primary tumor or metastasis that is suitable for HIFU-HT treatment.

    phase 1 other active

    1 trial

  4. Trial of the novel peroral anti-tumor treatment in patients with solid tumors

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed: tumors of lung, head and neck, colon, stomach, esophagus, breast, ovary and/or fallopian tube or primary peritoneal high-grade serous carcinoma

    phase 1 other active

    1 trial

  5. Vitamin B6-restricted diet + immunotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solid Tumor Cancer

    phase 1 other active

    1 trial

  6. Yang Yin Fu Zheng Jie Du therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 1 small molecule completed

    1 trial

  7. anti-BCMA/CD70-CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    CAR T Cell Therapy

    phase 1 mab active

    1 trial

  8. autologous FL-33 CAR T therapy

    Universal Integrated

    Refractory/Relapsed Acute Myeloid Leukaemia

    phase 1 small molecule active

    1 trial

  9. gene therapy

    Ultragenyx UK Limited

    Familial Hypercholesterolemia

    phase 1 other completed

    1 trial

  10. haploid allogeneic NK cell therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Myeloid Leukemia

    phase 1 mab active

    1 trial

  11. human Mesenchymal Stem Cell (MSC) infusion therapy

    CytoMed Therapeutics Ltd

    Aging Well

    phase 1 mab active

    1 trial

  12. locally manufactured adoptive cellular therapy (ACT) product

    Iovance Biotherapeutics B.V.

    Malignant Pleural Effusion

    phase 1 mab active

    1 trial

  13. standard chemotherapy medicine combined with Chinese herbs

    The First People's Hospital of Lianyungang

    Carcinoma, Non-Small-Cell Lung

    phase 1 small molecule active

    1 trial

  14. ​​AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors ​

    Amgen

    microsatellite instability high/mismatch repair deficient (MSI-H/dMMR) solid tumors

    phase 1 other active

    1 trial

  15. 6-month clopidogrel therapy

    Hospital Authority, Hong Kong

    Coronary Artery Disease

    approved small molecule completed

    1 trial

  16. AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CEFEPIME , CEFOTAXIME, SPIRAMYCIN , PIPERACILLIN AND BETA-LACTAMASE INHIBITOR

    Pari Pharma GmbH

    EA-COPD (with mechanical ventilation, invasive or non-invasive, or high-flow nasal oxygen therapy).

    approved small molecule active

    1 trial

  17. Anti-hypertensive therapy

    Arrowhead Pharmaceuticals Ireland Limited

    Hypertension

    approved small molecule completed

    1 trial

  18. Antiepileptic drug therapy

    United Therapeutics Europe Ltd

    Epilepsy

    approved small molecule active

    1 trial

  19. Antiretroviral therapy (ART)

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infection

    approved small molecule completed

    1 trial

  20. Behavior Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    approved other completed

    2 trials

  21. Camrelizumab + chemotherapy+Thalidomide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer

    approved small molecule active

    1 trial

  22. Conventional therapy + S (+)-Ketamine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    S-ketamine

    approved small molecule active

    1 trial

  23. Cymbalta 30 mg hard gastro-resistant capsules, Vimpat 50 mg film-coated tablets

    Disc Medicine

    chemotherapy-induced neuropathic pain

    approved small molecule active

    1 trial

  24. Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy

    The University of Hong Kong

    Fontan

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources